MedTrace Logo

Safety and Tolerability of MEDI9314 as Single Ascending Dose in Healthy Subjects

NCT02669667 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2019-06-04

Study results available
· View outcomes & findings →

Summary

This is a phase 1a randomized, blinded, placebo-controlled, single-ascending dose study to assess the safety and tolerability of MEDI9314 in healthy adult subjects

Conditions

  • Safety
  • Healthy Subjects

Interventions

DRUG

MEDI9314

single dose of MEDI9314

DRUG

placebo

single dose of placebo

Sponsors & Collaborators

  • MedImmune LLC

    lead INDUSTRY

Principal Investigators

  • Muna Albayaty, MBChB, FFPM · Parexel

  • Hakop Gevorkyan, MD · Parexel

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-02-18
Primary Completion
2016-11-17
Completion
2017-06-12

Countries

  • United States
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02669667 on ClinicalTrials.gov